At the news
? BEARISHIMPACT 6/10 424B5 filed Jul 2, 2026 at 16:06 ET
Abivax is raising approximately $759.8 million in net proceeds through a public offering of 6,400,000 ADSs at $125.00 per ADS, with an underwriter option for an additional 960,000 ADSs. The offering follows positive Phase 3 ABTECT Part 2 data for obefazimod in ulcerative colitis announced on June 29, 2026, and the company plans to submit an NDA in Q4 2026. The substantial dilution (~$110.78 per ADS) and the pre-revenue clinical-stage status make this a bearish event for existing shareholders despite the positive clinical data.
- Offering of 6,400,000 ADSs at $125.00 per ADS for total gross proceeds of $800,000,000.
- Net proceeds to Abivax are approximately $759.8 million ($666.8 million), or $874.1 million if underwriters exercise option for 960,000 additional ADSs.
- New investors will experience immediate dilution of $110.78 per ADS in as adjusted net tangible book value.
- Pro forma cash position increases to approximately $1.1 billion (€1,105 million) from €438 million as adjusted.
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access